Aitiologic Takes on Preeclampsia: Preparing for Large-Scale Validation after Presentation of Feasibility Study at FMF Conference in London

Today marked an exciting milestone for Aitiologic at The Fetal Medicine Advances Course in London! Dr. Rebecca Ertl presented the first feasibility results of the aitios® platform for tissue-specific liquid biopsy to over 1,500 clinicians and researchers.

In collaboration with Prof. Kypros Nicolaides and the Fetal Medicine Foundation (FMF), we demonstrated the potential to predict both preterm and term preeclampsia from a single first-trimester blood draw. In our study, we achieved AUCs of 0.85 and 0.84, respectively, with negative predictive values exceeding 99% at real-world disease incidences.

Why is this cfDNA Test a Potential Game-Changer?

Preeclampsia remains a leading cause of maternal and fetal morbidity worldwide. While early cfRNA-based detection for preterm preeclampsia was recently recognized as a key innovation by the TIME magazine, our data indicates potential benefits of a cfDNA-based, first-trimester approach for all subtypes. Compared to other approaches, aitios® is designed to integrate seamlessly into established NIPT workflows, potentially enabling an even earlier and more actionable window for intervention:

— Preterm Preeclampsia: Can still be prevented through timely pharmaceutical intervention.

— Term Preeclampsia: Risk can be significantly reduced through proactive monitoring and delivery planning.

We are truly encouraged by the response from the global community. As a next step, we are now preparing for a large-scale validation study to bring this early screening test closer to expecting mothers around the world.